CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 14 enrolled
Drug / intervention
NPC-01 +1 moredrug
Likely dose
NPC-01 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01253824
NCT01253824Phase 3Completed

Pharmacodynamics of NPC-01( 1mg Norethisterone and 0.02mg Ethinyl Estradiol) and IKH-01( 1mg Norethisterone and 0.035mg Ethinyl Estradiol); Effect of NPC-01 and IKH-01 on Serum Concentrations of Estradiol, Progesterone, FSH and LH.

Nobelpharma·interventional·Posted Dec 3, 2010·Updated Mar 6, 2025

In Brief

A Phase 3 clinical trial evaluating NPC-01 and IKH-01 for Healthy. Completed, enrolled 14 participants.

Detailed Summary

The purpose of this study is to compare the serum levels of estradiol, progesterone, FSH and LH in NPC-01 or IKH-01 one treatment cycle with those in before and after administration cycle.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 3, 2010
Enrollment StartJan 1, 2011
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 15.6 years ago

Interventions

NPC-01drug

NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol

IKH-01drug

IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol